ArcherDX, Inc. (RCHR)

ArcherDX will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Stock Price Chart

Key Info

Market Cap	n/a
Revenue (ttm)	55.91M
Net Income (ttm)	-54.93M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	n/a
Last Price	n/a
Previous Close	n/a
Change ($)	n/a
Change (%)	n/a
Day's Open	n/a
Day's Range	n/a
Day's Volume	n/a
52-Week Range	n/a

More Stats

Market Cap	n/a
Enterprise Value	n/a
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	n/a
Float	n/a
EPS (basic)	n/a
EPS (diluted)	n/a
FCF / Share	n/a

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	n/a
Short Ratio	n/a
Short % of Float	n/a
Beta	n/a

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	n/a
PB Ratio	n/a
Revenue	55.91M
Operating Income	n/a
Net Income	-54.93M
Free Cash Flow	n/a

Net Cash	n/a
Net Cash / Share	n/a
Gross Margin	n/a
Operating Margin	n/a
Profit Margin	-98.25%
FCF Margin	n/a
ROA	n/a
ROE	n/a
ROIC	n/a

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy	0
Overweight	0
Hold	0
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: n/a

Price Target

$n/a*

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year	2019	2018
Revenue	50.57	28.45
Revenue Growth	77.71%	-
Net Income / Loss	-40.98	-5.55

Numbers in millions USD.

Company Profile

Company Details

Full Name	ArcherDX, Inc.
Country	United States
Employees	337
CEO	Jason Myers

Stock Information

Ticker Symbol	RCHR
Stock Exchange	NASDAQ
Unique Identifier	NASDAQ: RCHR
IPO Date	Pending

Description

ArcherDX is a leading genomics company democratizing precision oncology. We offer a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. This empowers clinicians to control the sample, data, patient care and economics. Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development. We believe these benefits will drive broader adoption of precision oncology throughout the therapeutic continuum, improving patient care. Our product development platform, with our proprietary Anchored Multiplex PCR, or AMP, chemistry at the core, has enabled us to develop industry-leading products and services that allow for therapy optimization and cancer monitoring.